BI-1607
Advanced Solid Tumors
Phase 1/2Active
Key Facts
About BioInvent International
BioInvent International is a clinical-stage biotechnology company with a mission to transform cancer treatment through the discovery and development of novel, targeted antibody therapies. The company's strategy is anchored in its proprietary F.I.R.S.T.™ and n-CoDeR® platforms, which enable the identification of biologically relevant targets and the generation of fully human antibodies directly from human tissue. BioInvent has advanced a pipeline of proprietary and partnered candidates, most notably the anti-FcγRIIB antibody BI-1206, positioning itself as a key player in the next wave of immuno-oncology innovation.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |